ReviewBreathe (Sheffield, England)2025
Mediastinal staging of nonsmall cell lung cancer: what's new?
Review in Breathe (Sheffield, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic accuracy of CT-based radiomics for predicting occult lymph node metastasis in early-stage lung adenocarcinoma: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Prognostic and Diagnostic Value of Node-RADS for Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Multicenter Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Contemporary Lung Cancer Nodal Staging and Therapeutic Decision-Making in the 9th TNM Era.Cancers · 2026Review
- Synoptic Reporting Improves Quality of Endobronchial Ultrasound (EBUS): An Australian Multicentre Study.Cancers · 2026Article
- Beyond the lung: recognizing incidental breast lesions on chest computed tomography.Translational cancer research · 2026Review
- ERS Congress 2025: highlights from the Thoracic Oncology Assembly.ERJ open research · 2026Article
- Optimizing Lymph Node Staging in Non-Small Cell Lung Cancer Surgery: Evidence, Guidelines, and Quality Improvement Strategies.Journal of clinical medicine · 2026Review
- Article
- Risk-adaptive management of stage III NSCLC in the perioperative immunotherapy era: a critical synthesis and clinical framework.Frontiers in oncology · 2026Review
- Interventional pulmonology.Breathe (Sheffield, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we explore the importance of accurate mediastinal staging in nonsmall cell lung cancer, which directly impacts management options and prognosis. We outline the various means of staging, including radiological and interventional techniques, with a focus on the advantages and limitations of the different approaches. The review also identifies ways in which mediastinal staging has changed over time, particularly with the advent of effective endoscopic nodal sampling, and how emerging research and developments may lead to further adjustments in clinical practice. The role of multidisciplinary decision making, particularly in complex cases, remains integral to the process of mediastinal staging in lung cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.